|
|
ZIMULTI Acomplia Studies
Which studies have been carried out on ZIMULTI diet pills?
The ZIMULTI effects have been analyze to you in models experience them before being study to you on the human beings. They have been carried out four studies on ZIMULTI in patients in overweight and obese, for a total more than 6 600 patients, whose weight at the beginnig of the studies was in average between 94 and 104 kg. a study an other to the patients with diabetes of type 2 is interested in particular to the patients with abnormal levels of fat person of the blood and. The studies have compared the effect of ZIMULTI with that one of a placebo (fictitious treatment) on loss of weight in the course of a period comprised between one and two years. A study also has observed in that way the loss could be maintained during according to year. Sono inotre be lead four studies on ZIMULTI, confronted with placebo, which aid in order to stop to smoke on beyond 7 000 patients and measuring the effects of the somministrazione of the medicinal one for 10 weeks (a year in one of the studies) on the abandonment of the smoke and the fallen back ones in the successive year.
Sanofi-Aventis, developer of
In the wake of our discovery that Sanofi has been considering "Celnec" as a possible new name for Acomplia, sources pointed us to "Zimulti" as a slightly more euphonious possibility that also is getting a lot of Sanofi attention.
Just as it has with Celnec, Sanofi has engaged in a flurry of activity over the past couple of months around Zimulti, reviving efforts to secure the name with the U.S. Patent and Trademark Organization and registering dozens of Zimulti internet addresses. Zimulti Online
Some of Sanofi's barrage of internet registrations, which mostly took place on January 25th, would feed the speculation: acomplia-zimulti.com, zimulti-acomplia.com, zimulti-diet-pill.com, zimulti-rimonabant.com, and rimonabant-zimulti.com.
Sanofi, as with Celnec, has attempted to be sure that independent reporting on rimonabant -- if the name change goes forward -- is more difficult, by registering ZimultiReport.com and a variety of similar permutations. And as with Celnec, the company may be tipping us to its concerns about independent reporting by registering ZimultiSideEffects.com.
Ironically, the trademark application for Zimulti was originally filed by Aventis in 2003 (prior to its merger with Sanofi Synthélabo) as a name to be used for "pharmaceutical preparations, namely anti-infective preparations, preparations for the treatment of respiratory diseases, of cardiovascular diseases, of diabetes, of arthritis, of osteoporosis, of central nervous system, of cancer."
The U.S. Patent and Trademark Office approved Zimulti as a trademark on August 23rd, 2005.
Then three days before Christmas 2005, Aventis Pharma S.A. filed a new application with the U.S. Patent and Trademark Office seeking to register Zimulti for "pharmaceutical preparations for the prevention of cardiovascular diseases, for smoking cessation, and for the treatment of obesity."
This is the same description Sanofi-Aventis has used for Celnec and a variety of the other possible name-change alternatives for rimonabant that it has submitted to the USPTO.
The latest Zimulti application hasn't even been published for comment in the U.S. Federal Register, meaning that USPTO approval of this new application is at best many months away.
But FDA approval of the marketing of Acomplia/Rimonabant/Whatever in the United States increasingly appears to be many months off as well.
In the meantime, perhaps Sanofi -- if it decides to change the name of Acomplia -- can come up with something better than Celnec or Zimulti. Is it really possible that all the good pharmaceutical names have been exhausted?
Source:acomplia report
Diet Drug to Be Sold as Acomplia in Europe But Zimulti Looks Like the Name in U.S.
The highly anticipated diet drug Acomplia (rimonabant) will definitely be marketed in Europe under the name Acomplia, but developer Sanofi-Aventis has provided the strongest hints to date that it probably will sell the weight-loss pill in the United States as Zimulti.
"I can confirm that in Europe, we definitely will launch under the well-established trademark of Acomplia," said Hanspeter Spek, Sanofi's executive vice president, pharmaceutical operations, in response to a question about Zimulti http://www.zimultiacompliaonline.com from financial analysts on May 5th.
A committee of the European Medicines Agency (EMEA), the Committee for Medicinal Products for Human Use (CMPH), recommended approval of Acomplia and Zimulti as aids to weight-loss on April 28th, initially confusing some financial analysts who thought they might be two different drugs.
"Zimulti is nothing but a secondary trademark," Spek explained on May 5th. "We have applied for two registrations on the European level. Zimulti is nothing but a secondary trademark we may use later for technical reasons."
Those technical reasons probably have a lot to do with the United States, where the Food and Drug Administration -- which has delayed action on approval pending resolution of undisclosed issues -- appears to be objecting to the name Acomplia even though Sanofi has a U.S. trademark for the name.
While Spek did not address the question of what Acomplia may be called in the United States, Sanofi for months has referred to the drug by the generic name rimonabant when discussing the FDA approval process.
A variety of other names have been floated as possible replacements for
Acomplia, but Zimulti is looking more and more like Sanofi's choice for the U.S. trade name.
|
